Filing Flows › Stoke Therapeutics (STOK) › Q2 2026 › vs Q1 2026
Stoke Therapeutics (STOK) Q2 2026 vs Q1 2026 (quarter over quarter)
Stoke Therapeutics's revenue rose $3.1M (+50%) from $6.2M in Q1 2026 to $9.3M in Q2 2026.
Stoke Therapeutics, Q2 2026: revenue $9.3M (-32% year over year), operating margin -701.7%, net loss $61.6M, operating cash flow −$56.6M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $9.3M | $6.2M | $3.1M | +50% |
| Other income, net | $3.8M | $3.4M | $396K | +12% |
| Net loss | $61.6M | $50.0M | $11.6M | +23% |
| Costs & expenses | $74.8M | $59.6M | $15.1M | +25% |
| Operating costs | $74.8M | $59.6M | $15.1M | +25% |
| Research & development | $49.5M | $39.7M | $9.8M | +25% |
| SG&A | $25.3M | $20.0M | $5.3M | +26% |
| Operating cash sources | $67.8M | $69.8M | −$1.9M | -3% |
| Depreciation | $458K | $439K | $19K | +4% |
| Share-based compensation | $10.8M | $8.8M | $2.0M | +23% |
| Cash used in operations | $56.6M | $60.6M | −$4.0M | -7% |
| Net loss absorbed | $61.6M | $50.0M | $11.6M | +23% |
| Working capital & other | $6.2M | $19.8M | −$13.5M | -69% |
Questions
How much did Stoke Therapeutics's revenue grow quarter over quarter in Q2 2026?
Stoke Therapeutics's revenue rose $3.1M (+50%) from $6.2M in Q1 2026 to $9.3M in Q2 2026.